WO2000078795A3 - Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1) - Google Patents

Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1) Download PDF

Info

Publication number
WO2000078795A3
WO2000078795A3 PCT/US2000/015020 US0015020W WO0078795A3 WO 2000078795 A3 WO2000078795 A3 WO 2000078795A3 US 0015020 W US0015020 W US 0015020W WO 0078795 A3 WO0078795 A3 WO 0078795A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
useful
inhibitors
rufomycins
mrp
Prior art date
Application number
PCT/US2000/015020
Other languages
French (fr)
Other versions
WO2000078795A2 (en
Inventor
Palaniappan Kulanthaivel
Venkatraghavan Vasudevan
Original Assignee
Lilly Co Eli
Palaniappan Kulanthaivel
Venkatraghavan Vasudevan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Palaniappan Kulanthaivel, Venkatraghavan Vasudevan filed Critical Lilly Co Eli
Priority to AU60473/00A priority Critical patent/AU6047300A/en
Priority to EP00946770A priority patent/EP1192178A2/en
Publication of WO2000078795A2 publication Critical patent/WO2000078795A2/en
Publication of WO2000078795A3 publication Critical patent/WO2000078795A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides rufomycin factors and derivatives thereof useful as inhibitors of multi-drug resistant protein. As such these compounds are useful in combination therapy for the treatment of multi-drug resistant diseases. The present invention also provides novel rufomycin factors and derivatives thereof and their pharmaceutical compositions.
PCT/US2000/015020 1999-06-21 2000-06-08 Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1) WO2000078795A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU60473/00A AU6047300A (en) 1999-06-21 2000-06-08 Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistanceassociated protein-1 (mrp-1)
EP00946770A EP1192178A2 (en) 1999-06-21 2000-06-08 Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14036299P 1999-06-21 1999-06-21
US60/140,362 1999-06-21

Publications (2)

Publication Number Publication Date
WO2000078795A2 WO2000078795A2 (en) 2000-12-28
WO2000078795A3 true WO2000078795A3 (en) 2001-07-05

Family

ID=22490896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/015020 WO2000078795A2 (en) 1999-06-21 2000-06-08 Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1)

Country Status (4)

Country Link
EP (1) EP1192178A2 (en)
AU (1) AU6047300A (en)
PE (1) PE20010305A1 (en)
WO (1) WO2000078795A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
JP5766614B2 (en) 2009-01-09 2015-08-19 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ Neurogenesis-promoting compound
FR2949063B1 (en) * 2009-08-11 2011-09-30 Pf Medicament PHARMACEUTICAL COMPOSITION COMPRISING A DHA ESTER FOR PARENTERAL ADMINISTRATION
JP6126528B2 (en) 2010-07-07 2017-05-10 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ Neurogenesis-promoting compound
WO2014031986A1 (en) 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
CN106279370B (en) * 2016-09-06 2019-09-27 中国科学院南海海洋研究所 A kind of application of marine streptomyces and its cyclic peptide compounds in preparation Killing Mycobacterium Tuberculosis drug
CN106397544B (en) * 2016-09-06 2019-09-27 中国科学院南海海洋研究所 Cyclic peptide compound application in preparation of anti-tumor drugs
CN106497827B (en) * 2016-10-09 2019-08-02 中国科学院南海海洋研究所 A kind of engineering strain and its application of orientation production anti-tubercular and active compound for anti tumor
CN111303247B (en) * 2019-11-21 2022-03-22 中国科学院南海海洋研究所 Marine cyclopeptide compound and application thereof in preparation of mycobacterium tuberculosis resistant medicines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655879A (en) * 1960-02-08 1972-04-11 Takeda Chemical Industries Ltd Rufomycin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655879A (en) * 1960-02-08 1972-04-11 Takeda Chemical Industries Ltd Rufomycin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUJINO M. ET AL.: "Tryptophan Moiety of Rufomycin Homologs", CHEM.PHARM.BULL., vol. 12, no. 11, 1964, pages 1390 - 2, XP000945345 *
M.FOERTIER- BEAILIEU: "Y-A-T-IL des modalités de Surveillance Particulières Imposées par Certaines Thérapeutiques du Mélanome de Stade I?", ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, vol. 122, no. 5, 1995, pages 372 - 7, XP000945244 *

Also Published As

Publication number Publication date
EP1192178A2 (en) 2002-04-03
AU6047300A (en) 2001-01-09
WO2000078795A2 (en) 2000-12-28
PE20010305A1 (en) 2001-03-12

Similar Documents

Publication Publication Date Title
EE05585B1 (en) Indazole compounds and pharmaceutical compositions for the inhibition of protein kinases and their use
AU687909B2 (en) Protein kinase C inhibitors
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002089738A3 (en) Proteomimetic compounds and methods
CA2216535A1 (en) Protein kinase c inhibitors
SE9902987D0 (en) Novel compounds
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
CA2237221A1 (en) Protein kinase c inhibitor
BG101841A (en) Cellular adhesion inhibitors
IL125735A (en) Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compound
BR0313176A (en) Pyrazole compositions useful as gsk-3 inhibitors
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
DE69736441D1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISEASES
WO2000078795A3 (en) Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1)
BRPI0410049A (en) compound or a pharmaceutically acceptable salt or stereoisomer thereof, use of a compound, pharmaceutical composition, and pharmaceutical kit
AU1774097A (en) Pharmaceutical compositions for the treatment of rhinitis
CA2171446A1 (en) Pseudo- and non-peptide bradykinin receptor antagonists
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
WO2001087287A3 (en) Use of pyrazole derivatives for treating infertility
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
AU1189201A (en) Therapeutic compositions including protein kinase c inhibitors
WO2003051838A3 (en) Protein kinase inhibitors
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
MXPA03010259A (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof.
EP1232748A4 (en) Substituted nitrobenzene derivatives as medicines and other useful uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09979486

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000946770

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000946770

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000946770

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP